Marlborough, MA (PRWEB) September 11, 2008
Navilyst Medical, the manufacturer and global marketer of vascular access and fluid management medical devices, today announced its first in a series of new product launches as the company's newly branded entity. These new products are being debuted just four weeks after the company's introduction of its new corporate brand, following the previously announced divestiture from Boston Scientific. The products are designed to contribute to a hospital's compliance with OSHA regulations, CDC guidelines, as well as recently announced Joint Commission Hospital Patient Safety Goals.
The two new devices and enhanced PICC Convenience Kitting offerings expand Navilyst Medical's popular vascular access device product lines and can contribute to a hospital's infection prevention program. The new products will be premiered at Booth #202 at Annual Scientific Meeting of the Association for Vascular Access (AVA) in Savannah, Georgia this week.
These Navilyst Medical device images are available for download.
More Customized PICC Convenience Kits:
Navilyst Medical's market-leading offering of customized PICC kits manufactured by Navilyst Medical's Glens Falls, NY facility has been expanded. These enhancements include the new Xcela® Power Injectable PICC and a wider array of PICC insertion accessories and packaging. The market focus for the PICC Convenience Kitting program is on the bedside placement segment which accounts for over two-thirds of the approximately two million Peripherally Inserted Central Catheters (PICCs) that are sold in the U.S. annually. The program provides clinicians and hospitals the catheter and accessory choices they require for a procedure that is efficient and conducive to reducing the risk of accidental needlesticks (OSHA) and infections (CDC and Joint Commission). This also reduces costs from unnecessary supplies. These PICC Convenience Kits can be ordered with Navilyst Medical's proprietary PASV® valve catheters which are proven to reduce rates of catheter occlusions and infections--- another asset as hospitals prepare for the upcoming reimbursement restrictions by Centers for Medicare and Medicaid Services (CMS) for preventable complications which include catheter-related bloodstream infections.
New Xcela® Power Injectable Ports:
Port catheter systems are implanted in over 300,000 patients annually in the U.S. to provide a means for long-term delivery of fluids and medications including chemotherapy. For those who value the benefits of power injectability, Navilyst Medical's new Xcela Power Injectable Port s will offer the widest array of port options to satisfy the demands of physician preferences and patient characteristics. The titanium Xcela ports, available in standard and low profile sizes, offer durability and reduced size for ease of implantation and patient comfort. The plastic Xcela ports are light weight for patient comfort and offer radiolucence-reduced imaging artifact. Finally, the plastic/titanium hybrid port design option combines the durability of titanium with the light weight and radiolucence of plastic. All designs have a 5mL/sec with 300 psi infusion rating for use in contrast-enhanced imaging procedures. Xcela ports are compatible with the Company's new EZ Huber® safety Infusion Set.
New EZ Huber® Safety Infusion Set:
Navilyst Medical's new EZ Huber® Safety Infusion Set has a unique dual-action safety mechanism designed to reduce the risk of bloodborne pathogen exposure that threatens clinician safety and is a significant cost to the healthcare system. One safety feature shields the tip of the needle after the needle is withdrawn from the patient to prevent accidental needle sticks. The second safety feature is a protective cover that surrounds the entire needle after withdrawal to reduce exposure to aerosolized or splattered infusion fluids and blood. The EZ Huber® Safety Infusion Set is compatible with Navilyst Medical's new Xcela® Power Injectable Port and is rated for up to 5mL/sec at 300 psi for contrast-enhanced CT imaging procedures. Approximately 10 million Huber needle infusion sets are used annually in the U.S. to provide access to implanted port catheters.
Dave McClellan said today's announcement reflects Navilyst Medical's plans to be an aggressive device innovator. "These products that focus on both clinician and patient reflect our pledge to collaborate with our healthcare customers to deliver the technology and support they most need for efficient, safe, and effective interventional procedures They also met our pledge to do so with urgency while upholding the highest standards of quality, "said McClellan. "Our customers are excited---and they know there is more to follow."
About Navilyst Medical
Navilyst Medical, headquartered in Marlborough, MA, was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units. Its breakthrough devices, including the PASV® Valve Technology, expanded line of Xcela® PICCs and world-leading NAMIC® Fluid Management products, help hospitals to achieve safe, favorable outcomes for patients. The Company distributes its products worldwide and has its lead U.S. manufacturing facility in Glens Falls, NY. The name Navilyst combines the navi-- of navigation and the --lyst of catalyst, encompassing how a leading medical technology enterprise drives industry-changing innovation. For more information, please visit: http://www.navilystmedical.com. EZ Huber® is a registered trademark of Kerr Marketing, Inc.
FORWARD-LOOKING STATEMENTS: This Release contains forward-looking statements, including statements regarding development of Navilyst Medical's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.